Table 6.
List of the COVID-19 vaccines using LNPs.
| Vaccine | Developer | References |
|---|---|---|
| Approved by FDA | ||
| mRNA-1273 | ModernaTX, Inc. Phase 1: NCT04283461 (*) Phase 2: NCT04405076 (*) Phase 3: NCT04470427 (*) |
[127,128,147,150] |
| BNT162b2 | BioNTech SE and Pfizer Phase 1/2: NCT04380701 (*) Phase 2/3: NCT04368728 (*) |
[144] |
| In clinical evaluation stage | ||
| BNT162a1 | BioNTech SE and Pfizer Phase 1/2: NCT04380701 (*) Phase 2/3: NCT04368728 (*) |
[138,141] |
| BNT162b1 | ||
| BNT162c2 | ||
| ARCT-021 (mRNA Lunar-Cov19) | Arcturus Therapeutics and Duke-NUS Phase 1/2: NCT04480957 |
[153] |
| COVAC1 (LNP-nCoVsaRNA) | Imperial College London Phase 1: ISRCTN17072692 (*) |
[140,151,152] |
| ChulaCov19 mRNA vaccine | Chula Vaccine Research Center/University of Pennsylvania Phase 1: NCT04566276 (*) |
[140] |
| SARS-VoV-2 mRNA vaccine | Shulan (Hangzhou) Hospital; Center for Disease Control and Prevention of Guangxi Zhuang Autonomous Region Phase 1: ChiCTR2000034112 (*) |
[160] |
| D614G variant LNP-encapsulated mRNA | Globe Biotech Ltd. | [140] |
| In pre-clinical stage | ||
| LNP-encapsulated mRNA encoding S | Max-Planck-Institute of Colloids and Interfaces | [140] |
| LNP-mRNA | Translate Bio/Sanofi Pasteur | [140] |
| LNP-mRNA | CanSino Biologics/Precision NanoSystems | [140] |
| LNP-encapsulated mRNA | University of Tokyo/Daiichi-Sankyo | [140] |
| Peptide antigens formulated in LNP | IMV Inc | [140] |
| LNP-encapsulated mRNA encoding RBD | Fudan University/ Shanghai JiaoTong University/RNACure Biopharma | [140,159] |
| LNP-encapsulated mRNA encoding the full-length wild-type (WT) S | [161] | |
| LNP-encapsulated mRNA cocktail encoding VLP | [140,161] | |
(*) ClinicalTrials.gov indentifier.